Protective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system

dc.contributor.authorAbbas, N.en
dc.contributor.authorZou, L. P.en
dc.contributor.authorPelidou, S. H.en
dc.contributor.authorWinblad, B.en
dc.contributor.authorZhu, J.en
dc.date.accessioned2015-11-24T18:55:56Z
dc.date.available2015-11-24T18:55:56Z
dc.identifier.issn0891-6934-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18958
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectAnti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic useen
dc.subjectChemokine CCL2/biosynthesisen
dc.subjectChemokine CCL4en
dc.subjectChemokine CXCL2en
dc.subjectChemokines/biosynthesisen
dc.subjectDown-Regulation/drug effectsen
dc.subjectHumansen
dc.subjectInflammation Mediators/metabolismen
dc.subjectInterferon-gamma/biosynthesisen
dc.subjectInterleukin-4/biosynthesisen
dc.subjectMacrophage Inflammatory Proteins/biosynthesisen
dc.subjectMaleen
dc.subjectMyelin P2 Protein/immunologyen
dc.subjectNeuritis, Autoimmune, Experimental/*drug therapy/*immunology/pathologyen
dc.subjectPeripheral Nerves/drug effects/immunology/pathologyen
dc.subjectPhosphodiesterase Inhibitors/administration & dosage/*therapeutic useen
dc.subjectRatsen
dc.subjectRats, Inbred Lewen
dc.subjectRolipram/administration & dosage/*therapeutic useen
dc.subjectUp-Regulation/drug effectsen
dc.titleProtective effect of Rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-gamma and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous systemen
heal.abstractRolipram, a phosphodiesterase type 4 inhibitor, is reported to have anti-inflammatory effects. It can markedly downregulate antigen-driven T cell proliferation and suppress TNF-(alpha and TNF-beta production in vitro and in vivo, which have led to its use in the treatment of a number of autoimmune disorders including experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune neuritis (EAN). EAN is a CD4+ T cell-mediated demyelinating autoimmune disease of peripheral nervous system (PNS) that represents an animal model for the study of the immunopathogenesis and immunotherapy of Guillain-Barre syndrome (GBS) in human. In the previous study, we reported that suppression of EAN by Rolipram was associated with down-regulated myelin antigen-induced T cell responses as well as downregulated IFN-gamma and TNF-alpha production. Here we report that EAN induced in Lewis rats by inoculation with the PNS P2 protein peptide 57-81 and Freund's complete adjuvant (FCA), was strongly suppressed by Rolipram administered twice daily intraperitoneally from day 9 post immunization (p.i.), i.e. after onset of clinical EAN to day 18 p.i. This clinical effect was associated with dose-dependent down-regulated production of IFN-gamma and the chemokines macrophage inflammatory protein-1 alpha (MIP-1 alpha, MIP-2 and monocyte chemotactic protein-1(MCP-1) as well as up-regulated IL-4 production in sciatic nerve sections from Rolipram-treated EAN rats at maximum of clinical EAN, i.e. on day 14 p.i.. These findings suggest that Rolipram may be useful in certain T cell-dependent autoimmune diseases and inflammatory neuropathies. These observations call for further studies on the potential role of Rolipram in the treatment of autoimmune diseases.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11078155-
heal.journalNameAutoimmunityen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: